Asem Ali is an Endocrinology/Metabolic physician affiliated with University of Massachusetts Chan Medical School. OpenAlex indexes 22 publications with 685 citations (h-index 13); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
732 Harrison Ave, Fl 2
Preston Bldg, Endocrinology
Boston, MA 021182309
Telephone
617-638-7470Provider last certified this registry record 11 Jul 2024.
Clinical trials
- Metabolic Surgery Versus Medical Management for Resolution of Type II Diabetes
Sponsor: David Bradley MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SANOFI-AVENTIS U.S. LLCProgram year20251 payment
- Novo Nordisk IncProgram year20251 payment
- Janssen Pharmaceuticals, IncProgram year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
79.4%GLP-1 receptor agonist28.7%Ozempic39%Trulicity33%Mounjaro28%Part D≥64 patientsInsulin Analog23.2%Humalog Kwikpen U-10018%Lantus Solostar17%Tresiba Flextouch U-10012%Novolog Flexpen10%Basaglar Kwikpen U-10010%Lantus5%Humalog5%Novolog5%Insulin Lispro Kwikpen U-1004%Toujeo Max Solostar3%Toujeo Solostar3%Tresiba Flextouch U-2003%Tresiba3%Admelog Solostar3%Part D<11 patients+ 7 more classes in this area
Cardiovascular
14%Statin5.4%Rosuvastatin Calcium51%Atorvastatin Calcium49%Part D≥22 patientsAngiotensin receptor blocker (ARB)2%Losartan Potassium100%Part D≥16 patients+ 5 more classes in this area
Hormonal (systemic)
3.4%l-Thyroxine1.8%Levothyroxine Sodium100%Part D≥13 patientsThyroid Hormone Synthesis Inhibitor1%Methimazole100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Accuracy of a Continuous Glucose Monitor in the Intensive Care Unit
Diabetes Technology & Therapeutics
2026 - SAT-464 Management of an Aggressive Growth Hormone Producing Pituitary Macroadenoma
Journal of the Endocrine Society
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Fernando Martinez, MD
University of Massachusetts Chan Medical School
Joel Gore, MD
University of Massachusetts Chan Medical School
Johanna Seddon, MD
University of Massachusetts Chan Medical School
Andres Schanzer, MD
University of Massachusetts Chan Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”